152
Participants
Start Date
March 19, 2021
Primary Completion Date
December 23, 2022
Study Completion Date
August 23, 2024
Trastuzumab deruxtecan
Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL \[ie, 100 mg/5 mL\]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.
Chang Gung Memorial Hospital CGMH - LinKou Branch, Taoyuan District
National Cheng Kung University Hospital NCKUH, Tainan City
Asan Medical Center, Seoul
Princess Alexandra Hospital, Woolloongabba
St John of God Subiaco Hospital, Subiaco
Samsung Medical Center, Seoul
National Taiwan University Hospital, Taipei
Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano
National Hospital Organization Kyushu Cancer Center, Fukuoka
Assistance Publique Hopitaux de Marseille AP-HM, Hopital NORD, Marseille
Humanitas Cancer Center Istituto Clinico Humanitas, Rozzano
IRCCS Istituto Europeo di Oncologia, Milan
Virgina Cancer Specialists, Fairfax
Clinica Universidad de Navarra, Madrid
Hospital Universitario Fundacion Jimenez Diaz, Madrid
Hospital 12 de Octubre, Madrid
Chungbuk National University Hospital, Jungbuk
Clinica Univ. de Navarra - P, Pamplona
CHU toulouse - hôpital Larrey, Toulouse
AdventHealth Orlando, Orlando
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Hopital Pontchaillou, Rennes
Sarah Cannon Research Institute, Nashville
Norton Cancer Institute, Louisville
Chung Shan Medical University Hospital, Taichung
Taichung Veterans General Hospital, Taichung
SC Oncologia, AOU Policlinico Modena, Modena
CHU Nantes, Saint-Herblain
Hospital Universitari i Politècnic La Fe, Valencia
Henry Ford Cancer Institute/Henry Ford Hospital, Detroit
University of Michigan, Detroit
Ospedale San Luca, Lucca
Washington University School of Medicine, St Louis
Centre Leon Berard, Lyon
University of Colorado Denver - Anschutz Medical Campus, Aurora
Istituto Nazionale Tumori Fondazione G. Pascale di Napoli Strutturadi Oncologia, Napoli
Gustav Roussy, Villejuif
Massachusetts General Hospital (MGH) - Hematology/Oncology, Boston
Dana-Farber Cancer Institute, Boston
University Health Network, Toronto
Aichi Cancer Center Hospital, Chikusa
National Cancer Central Hospital, Chūōku
National Cancer Center Hospital East, Kashiwa
Okayama University Hospital, Okayama
Kindai University Hospital, Ōsaka-sayama
Netherlands Cancer Institute, Amsterdam
Erasmus MC, Rotterdam
Seoul National University Bundang Hospital, Seongnam
Seoul National University Hospital, Seoul
Hospital Universitario Vall d'Hebron, Barcelona
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
Daiichi Sankyo
INDUSTRY